Get to know our clinical trials
Cevostamab in combination with pomalidomide and dexamethasone versus standard therapy in previously treated patients with multiple myeloma.
THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTS, BOTH BENEFICIAL AND ADVERSE, OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH THE STANDARD TREATMENT SELECTED BY THE STUDY PHYSICIAN—DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (DPD), ELOTUZUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD), OR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE (KD)—IN PEOPLE WITH MULTIPLE MYELOMA.
Technical Summary
- PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD THERAPY IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF TREATMENT.
- Code EudraCT: 2025-524028-23-00
- Protocol number: CO46096
- Promoter: Roche Farma, S.A.
- Molecule/Drug: Cevostamab en combinación con pomalidomida y dexametasona
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.